ArticleBlood2015
Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 110 citations in OpenAlex.
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Nature medicine · 2023Trial
- Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism.The Journal of clinical investigation · 2025Article
- The Imbalanced Patterns and Clinical Significance of Cytokines in Acute Myeloid Leukemia Microenvironment.Immunity, inflammation and disease · 2025Article
- EGR3 Promotes Glioblastoma Cell Growth with Upregulation of MYC and CDK1.International journal of molecular sciences · 2025Article
- Iron overload promotes myeloid differentiation of normal hematopoietic stem cells and educates macrophage mediated immunosuppression in acute myeloid leukemia.Frontiers in immunology · 2025Article
- Small extracellular vesicles derived from acute myeloid leukemia cells promote leukemogenesis by transferring miR-221-3p.Haematologica · 2024Article
- EGR3 Inhibits Tumor Progression by Inducing Schwann Cell-Like Differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Intravital Microscopy to Study the Effect of Matrix Metalloproteinase Inhibition on Acute Myeloid Leukemia Cell Migration in the Bone Marrow.Methods in molecular biology (Clifton, N.J.) · 2024Article
- LinCell proliferation · 2023Article
- Interlukin-4 weakens resistance to stress injury and megakaryocytic differentiation of hematopoietic stem cells by inhibiting Psmd13 expression.Scientific reports · 2023Article
- Article
- Sox13 and M2-like leukemia-associated macrophages contribute to endogenous IL-34 caused accelerated progression of acute myeloid leukemia.Cell death & disease · 2023Article
- Role of the bone marrow vascular niche in chemotherapy for MLL-AF9-induced acute myeloid leukemia.Blood science (Baltimore, Md.) · 2023Article
- Chemotherapy-induced thrombocytopenia: literature review.Discover oncology · 2023Review
- Emerging roles of extracellular vesicles in normal and malignant hematopoiesis.The Journal of clinical investigation · 2022Review
- The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.iScience · 2022Article
- Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness.Blood advances · 2022Article
- JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.Blood cells, molecules & diseases · 2021Article
- XIST promotes apoptosis and the inflammatory response in CSE-stimulated cells via the miR-200c-3p/EGR3 axis.BMC pulmonary medicine · 2021Article
- DPP4Leukemia · 2021Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by"Blood feuds".2015
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Cytopenias resulting from the impaired generation of normal blood cells from hematopoietic precursors are important contributors to morbidity and mortality in patients with leukemia. However, the process by which normal hematopoietic cells are overtaken by emerging leukemia cells and how different subsets of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) are distinctly influenced during leukemic cell infiltration is poorly understood. To investigate these important questions, we used a robust nonirradiated mouse model of human MLL-AF9 leukemia to examine the suppression of HSCs and HPCs during leukemia cell expansion in vivo. Among all the hematopoietic subsets, long-term repopulating HSCs were the least reduced, whereas megakaryocytic-erythroid progenitors were the most significantly suppressed. Notably, nearly all of the HSCs were forced into a noncycling state in leukemic marrow at late stages, but their reconstitution potential appeared to be intact upon transplantation into nonleukemic hosts. Gene expression profiling and further functional validation revealed that Egr3 was a strong limiting factor for the proliferative potential of HSCs. Therefore, this study provides not only a molecular basis for the more tightened quiescence of HSCs in leukemia, but also a novel approach for defining functional regulators of HSCs in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.